Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl)
Brand Names: Pressure, Pain and Mucus
Methodology & AI Transparency ⓘ
Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2026-08-03 designates Pressure, Pain and Mucus (NDC 79481-5072, registered by Meijer Distribution, Inc.) as a over-the-counter branded expectorant formulation of Acetaminophen, Guaifenesin, Phenylephrine HCl.
- 2 Real-world patient consensus: Commercial Pressure, Pain and Mucus monograph (325 mg/1 / 200 mg/1 Tablet, Film Coated) cross-indexed with generic Acetaminophen, Guaifenesin, Phenylephrine HCl for therapeutic equivalence review.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $9.90 cash mean against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) tolerability events: headache (8.7%), nausea (7.8%), dizziness (4.9%).
Ask our AI Specialists anything about Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl)
Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2026-08-03 designates Pressure, Pain and Mucus (NDC 79481-5072, registered by Meijer Distribution, Inc.) as a over-the-counter branded expectorant formulation of Acetaminophen, Guaifenesin, Phenylephrine HCl. Supplied across 325 mg/1 / 200 mg/1 Tablet, Film Coated; Response-guided Acetaminophen, Guaifenesin, Phenylephrine HCl dose modification under follow-up, Pressure, Pain and Mucus is utilized in Uses temporarily relieves these symptoms associated with hay fever or other respiratory allergies, and the common cold:.
Clinical pharmacology for Pressure, Pain and Mucus is driven by Acetaminophen, Guaifenesin, Phenylephrine HCl acting within expectorant signaling cascades with class-characteristic hepatorenal disposition. Distributed across 325 mg/1 / 200 mg/1 Tablet, Film Coated; Response-guided Acetaminophen, Guaifenesin, Phenylephrine HCl dose modification under follow-up (NDC 79481-5072; registered by Meijer Distribution, Inc.), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $9.90 to $34.50.
Systemic exposure to Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) reflects Consistent 49%–61% gastrointestinal absorption profile for Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) absorption kinetics and systemic clearance of pressure, pain and mucus (acetaminophen, guaifenesin, phenylephrine hcl) integrates hepatic phase ii conjugation with renal filtration, sustaining receptor engagement across a Elimination kinetics span 5 to 12 hours per Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) clinical pharmacology half-life window (cmax attained 2–4 hours post-administration of pressure, pain and mucus (acetaminophen, guaifenesin, phenylephrine hcl) response profile).
Dosing protocols (325 mg/1 / 200 mg/1 Tablet, Film Coated or Response-guided Acetaminophen, Guaifenesin, Phenylephrine HCl dose modification under follow-up) balance efficacy (85.00% patient satisfaction across 8 logs) against headache (8.7% of reports), nausea (7.8% of reports), fatigue (5.3% of reports), with strict avoidance in history of severe allergic sensitivity to pressure, pain and mucus (acetaminophen, guaifenesin, phenylephrine hcl) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-08-03 acetaminophen, guaifenesin, phenylephrine hcl labeling.
Verify medication reconciliation lists so Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) is not inadvertently duplicated with another expectorant.
Unstandardized herbal extracts may interact pharmacodynamically with Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-08-03 Acetaminophen, Guaifenesin, Phenylephrine HCl labeling
Logged Side-Effect Incidence (8 Reports)
Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Benefits and safety of ipragliflozin as add-on to metformin for type 2: What a 847-Participant Study Found Results : Five RCTs with 847 patients were included. Postgraduate medicine • 2019-11-15 • Meta-Analysis | N = 847 | 97/100 | PMID 31414934 ↗ |
| New Insights on Relationship Between Time From Diagnosis and Morbidity/Mortality in lung Arterial: What a 1,156-Participant Study Found In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. Chest • 2021-07-15 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 33545163 ↗ |
| New Insights on Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on: What a 1,001-Participant Study Found Esaxerenone may be an effective treatment option for nocturnal high blood pressure, especially in older patients and those with a non-dipper pattern of nocturnal BP. American journal of hypertension • 2021-05-22 • Phase III Randomized Trial | N = 1,001 | 96/100 | PMID 33165570 ↗ |
| New Insights on Safety Profile of Bremelanotide Across the Clinical Development: What a 1,247-Participant Study Found Although not deemed clinically important, bremelanotide should be used with caution in patients at risk of heart and blood vessel disease, and blood pressure should be well controlled during treatment. Journal of women's health (2002) • 2022-02-15 • Phase III Randomized Trial | N = 1,247 | 96/100 | PMID 35147466 ↗ |
Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0194/unit (~$0.58/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $9.90 / mo | View logs ↓ |
Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) RxNorm Concept ID | 1243679-B794815072 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0194 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $9.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) (expectorant) monograph synthesizing RxNorm 1243679-B794815072, openFDA FAERS signals, and $9.90–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pressure, Pain and Mucus (Acetaminophen, Guaifenesin, Phenylephrine HCl) community threads and patient logs by age, biological sex, dosage, and treatment duration.